Skip to content

Study · Randomized controlled trial · n = 11 · 1993

5 results

Intranasal glucagon treatment relieves hypoglycaemia in children with type 1 (insulin-dependent) diabetes mellitus.

Stenninger E, Aman J

Diabetologia1 Oct 1993Cited by 19 (Europe PMC)

PMID8243872 (opens in a new tab)DOI10.1007/bf02374475 (opens in a new tab)PepBankPUB-08243872
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialPharmacokinetics

    In diabetic children, subcutaneous glucagon produced higher and more sustained plasma concentrations than nasal glucagon.

    In plain wordsIn diabetic children, injected glucagon produced higher and longer-lasting drug levels than nasal glucagon.

    Peptide
    Glucagon
    Outcome
    IncreasePlasma glucagon concentrations
    Study

    n = 11

    Comparator
    1 mg intranasal glucagon
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    0.5 mg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Subcutaneous injections induced higher and more sustained plasma glucagon concentrations but the children suffered more often from nausea than when they were treated intranasally.
    2 context sentences
    Summary · context
    The aim of the present study was to compare intra-nasal glucagon with subcutaneous glucagon as a treatment of insulin-induced hypoglycaemia in 11 children, 7-12 years old, with Type 1 (insulin-dependent) diabetes mellitus.
    Summary · context
    One milligram of intranasal glucagon or 0.5 mg of subcutaneous glucagon was given in a randomized order.
  2. 02HumanRandomized controlled trialSafety outcome

    In diabetic children, nausea occurred more often after subcutaneous glucagon than nasal glucagon.

    In plain wordsIn diabetic children, injected glucagon caused nausea more often than nasal glucagon.

    Peptide
    Glucagon
    Outcome
    IncreaseNausea
    Study

    n = 11

    Comparator
    1 mg intranasal glucagon
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    0.5 mg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Subcutaneous injections induced higher and more sustained plasma glucagon concentrations but the children suffered more often from nausea than when they were treated intranasally.
    2 context sentences
    Summary · context
    The aim of the present study was to compare intra-nasal glucagon with subcutaneous glucagon as a treatment of insulin-induced hypoglycaemia in 11 children, 7-12 years old, with Type 1 (insulin-dependent) diabetes mellitus.
    Summary · context
    One milligram of intranasal glucagon or 0.5 mg of subcutaneous glucagon was given in a randomized order.
  3. 03HumanNon-randomized trialEfficacy outcome

    In diabetic children, intranasal glucagon increased blood glucose by 1.5 +/- 0.2 mmol/l above nadir at 15 min.

    In plain wordsIn diabetic children, nasal glucagon increased blood glucose above its lowest level.

    Peptide
    Glucagon
    Outcome
    IncreaseBlood glucose rise at 15 min, intranasal
    Study

    n = 11

    Comparator
    Glucose nadir
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1 mg · intranasalAs given in this study (human).

    Measurements

    Blood glucose rise above nadir at 15 min
    1.5 mmol/l
    Intranasal glucagon 1 mg; +/- 0.2 reported

    Source sentences

    Summary
    At 15 min after the administrations of either intranasal or subcutaneous glucagon, the blood glucose concentration increased by 1.5 +/- 0.2 mmol/l or 1.7 +/- 0.2 mmol/l above the glucose nadir, respectively.
    2 context sentences
    Summary · context
    The aim of the present study was to compare intra-nasal glucagon with subcutaneous glucagon as a treatment of insulin-induced hypoglycaemia in 11 children, 7-12 years old, with Type 1 (insulin-dependent) diabetes mellitus.
    Summary · context
    One milligram of intranasal glucagon or 0.5 mg of subcutaneous glucagon was given in a randomized order.
  4. 04HumanNon-randomized trialEfficacy outcome

    In diabetic children, subcutaneous glucagon increased blood glucose by 1.7 +/- 0.2 mmol/l above nadir at 15 min.

    In plain wordsIn diabetic children, injected glucagon increased blood glucose above its lowest level.

    Peptide
    Glucagon
    Outcome
    IncreaseBlood glucose rise at 15 min, subcutaneous
    Study

    n = 11

    Comparator
    Glucose nadir
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.5 mg · subcutaneousAs given in this study (human).

    Measurements

    Blood glucose rise above nadir at 15 min
    1.7 mmol/l
    Subcutaneous glucagon 0.5 mg; +/- 0.2 reported

    Source sentences

    Summary
    At 15 min after the administrations of either intranasal or subcutaneous glucagon, the blood glucose concentration increased by 1.5 +/- 0.2 mmol/l or 1.7 +/- 0.2 mmol/l above the glucose nadir, respectively.
    2 context sentences
    Summary · context
    The aim of the present study was to compare intra-nasal glucagon with subcutaneous glucagon as a treatment of insulin-induced hypoglycaemia in 11 children, 7-12 years old, with Type 1 (insulin-dependent) diabetes mellitus.
    Summary · context
    One milligram of intranasal glucagon or 0.5 mg of subcutaneous glucagon was given in a randomized order.
  5. 05HumanNon-randomized trialEfficacy outcome

    In diabetic children, the maximal blood glucose rise after nasal glucagon occurred at 25 min.

    In plain wordsIn diabetic children, the greatest glucose rise after nasal glucagon occurred at 25 minutes.

    Peptide
    Glucagon
    Outcome
    Not applicableTime to maximal glucose rise
    Study

    n = 11

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1 mg · intranasalAs given in this study (human).

    Measurements

    Time to maximal blood glucose rise
    25 min
    After nasal glucagon

    Source sentences

    Summary
    After nasal administration, the maximal rise in blood glucose was seen after 25 min.
    2 context sentences
    Summary · context
    The aim of the present study was to compare intra-nasal glucagon with subcutaneous glucagon as a treatment of insulin-induced hypoglycaemia in 11 children, 7-12 years old, with Type 1 (insulin-dependent) diabetes mellitus.
    Summary · context
    One milligram of intranasal glucagon or 0.5 mg of subcutaneous glucagon was given in a randomized order.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.